Biomarker Shows Promise In Scleroderma PDF Print E-mail
Thursday, 23 May 2013 21:16
A biomarker that can be used to screen Scleroderma patients for pulmonary hypertension has shown promise in a proof of concept study. Researchers from St Vincent’s in Melbourne found asymmetric dimethylarginine (ADMA) levels had an acceptable high specificity and sensitivity for detecting the complication, particularly when used in conjunction with NT-proBNP.

When combined with the biomarker commonly used in heart failure the test had a sensitivity of 93.3% and a specificity of 100% for detecting PAH, said author Vivek Thakker (pictured) from St Vincent’ in Melbourne who presented his poster during a tour led by Wendy Stevens from the same hospital.

Testing for ADMA was not widely available but cost $60 a test, significantly cheaper than echocardiography, he said.

But the results needed to be validated in larger cohorts, he added.

Source: Rheumatology Update (2013)
 
More articles :

» The Vascular Microenvironment and Systemic Sclerosis

Tracy Frech, Nathan Hatton, Boaz Markewitz, Mary Beth Scholand, Richard Cawthon, Amit Patel, and Allen SawitzkeReceived 5 April 2010; Revised 28 May 2010; Accepted 6 July 2010The role of the vascular microenvironment in the pathogenesis Systemic...

» Preterm Delivery a Risk in Systemic Sclerosis

Many women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Special Surgery Scientists To Share Advances in Lupus and Related Conditions

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of...

» Immune Therapy Developed for Atherosclerosis

is when plaque builds up in the arteries; and it can cause serious problems in the heart. However new strategies are helping patients combat atherosclerosis; and could change the treatment landscape of heart disease, all together.It was in the...

» Liver Autoantibodies in Patients with Scleroderma

Thelma L. Skare & Renato M. Nisihara & Osvaldo Haider & Pedro M. Azevedo & Shirley R. R. UtiyamaReceived: 5 January 2010 / Revised: 13 August 2010 / Accepted: 26 September 2010# Clinical Rheumatology 2010Association between...